99Tc-MDP for Thyroid-Associated Ophthalmopathy

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 16, 2017

Primary Completion Date

December 30, 2018

Study Completion Date

March 31, 2019

Conditions
Thyroid-Associated Ophthalmopathy
Interventions
DRUG

Methylprednisolone

500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. once a week for 6 weeks.

DRUG

99Tc-MDP(99Technetium-Methylenediphosphonate Injection)

15mg i.v. infusion once a day for 10 days, 20 days apart, received 3 courses of infusions.

Trial Locations (1)

116001

Affiliated Zhongshan Hospital of Dalian University, Dalian

All Listed Sponsors
lead

Dalian University

OTHER

NCT03948191 - 99Tc-MDP for Thyroid-Associated Ophthalmopathy | Biotech Hunter | Biotech Hunter